InSphero Webinar Program
- Liver Models and Lipid Metabolism: From Monolayer to Microtissue
- Bioluminescent Assays and 3D Models for Diabetes Research
- High Content Imaging and Analysis
- Modeling Drug-Drug Interactions with Organ-on-a-Chip Technology
- Microfluidic Insulin Release Dynamics
- Drug-Induced Liver Injury (DILI) Screening
- Teasing out Mechanisms of DILI
- NASH Drug Discovery
Upcoming Live Webinars
Mechanistic Approaches Using 3D Microtissues to Evaluate Preclinical and Clinical Drug-Induced Liver Injury
In this webinar, hosted by the American College of Toxicology, InSphero CSO Dr. Wolf will present novel in vitro models and methodologies for studying drug-induced liver injury (DILI).
Human 3D liver microtissues or spheroids comprise of hepatocytes, Kupffer cells, and liver endothelial cells. They can be used for investigating a broad range of experimental conditions by various analytical methods, from liver enzyme markers and histological techniques to the latest omics technologies.
Major applications of human 3D microtissues are hazard identification in the early discovery phase and in mechanistic investigative toxicology. If DILI is observed in preclinical animal models, “cross species” animal liver microtissues can be used to recapitulate observed in vivo effects by mechanistic studies in vitro.
With the “causality assay” framework, a specific pathway modulator (either an enhancer/agonist or inhibitor/antagonist) is co-incubated with the DILI compound. Dr. Wolf will show examples of successful applications of causality assays for the deconvolution of major DILI mechanisms—and offer a vision for the future of 3D in vitro tools for translational liver toxicology.
Wednesday, October 21, 2020
11:30 AM ET | 4:30 PM BST | 5:30 PM CET
Liver Models and Lipid Metabolism: From Monolayer to Microtissue
Non-alcoholic fatty liver disease (NAFLD) begins with excessive fat accumulation in the liver. Effectively mimicking this disease at the bench requires complex 3D in vitro liver models and assays that reflect the human disease biology and response to treatments. How do you choose which 3D liver model is right for your research? Which biochemical assays and endpoints should you use to monitor relevant markers, such as triglycerides, glucose, ATP, and LDH?
The webinar will be led by two experts who leverage years of practical experience in the field:
- Dr. Michael Valley, a Senior Research Scientist at Promega with extensive experience in developing luminescent and metabolic assays.
- Dr. Sue Grepper, a Senior Application Scientist at InSphero with a strong background in 3D liver models, liver toxicity and disease, metabolic diseases.
They will discuss how non-alcoholic fatty liver disease (NAFLD) can be studied with complex 3D in vitro models like our 3D InSight™ Human Liver Disease Platform and how to apply latest biochemical assays to achieve your research goals.
In this joint webinar, you will learn:
- The basics of human fatty liver disease and the challenges of modelling NAFLD in vitro
- The range of different types of 3D liver models and easy-to-use biochemical assays
- How to apply the latest 3D in vitro cell technologies to evaluate the effects of therapies that target early-stage NAFLD
Submit a question when you register by Friday, September 18, and we’ll pass it on to the speakers to consider addressing in their talks or during the live discussion.
Method Validation and 3D Islet Models for Diabetes Research
Are you using 3D pancreatic islet cells for diabetes research? Want to learn more about validating assays to use with 3D model systems?
Join us for this webinar as Dr. Terry Riss from Promega presents the approach used to verify bioluminescent assay performance in 3D models, including assays to measure cell viability, apoptosis, and hormone secretion. Dr. Joan Mir from InSphero will introduce the properties of Islet Microtissues and describe applications for using these validated assays. This will be a great opportunity to learn more about our 3D InSight™ Islet Microtissues and their benefits for diabetes research.
In this webinar, you will learn about:
- 3D assays for cell viability, apoptosis and hormone secretion
- Strategies for validating 3D assays
- Using 3D assays with pancreatic islet microtissues
Predicting Metabolism-Related Drug-Drug Interactions with Organ-on-a-Chip Technology
Drug-drug interactions (DDIs) occur when the pharmacological activity of one drug is altered by a second drug. As multimorbidity and polypharmacotherapy are becoming more common due to aging populations, the risk of DDIs is rapidly increasing. In this webinar, InSphero Head of Technologies and Platforms Dr. Olivier Frey and Dr. Christian Lohasz from the Bio Engineering Laboratory at ETH Zurich, will present a scalable, gravity-driven microfluidic system for studying DDIs in a multi-tissue network comprised of 3D human liver and tumor models, using drug combinations known to cause DDIs in vivo. You will learn:
- Challenges of modeling DDIs in vitro and how multi-tissue microfluidic networks enable DDI testing
- Characteristics of 3D human liver and tumor models suitable for pharmacological investigations
- Bio-engineering considerations for multi-organ networks in preclinical substance testing
- Results of proof-of-concept studies using anti-cancer prodrugs to identify and quantify DDIs
- Future outlook for microfluidic multi-tissue networks in pharmacokinetics
Implementing High Resolution, High Content Image Analysis with Multicellular 3D Spheroid Models
High content analysis (HCA) of 3D spheroid models has the potential to provide valuable information to help researchers untangle disease pathophysiology and assess novel therapies more effectively. However, the transition from 2D monolayer models to dense 3D spheroids in HCA applications is not trivial and requires 3D-optimized protocols, instrumentation, and resources. In this webinar, InSphero Senior Application Scientist and SBI2 President Elect Judi Wardwell-Swanson and Yokogawa Life Sciences Senior Executive Dr. Gerd Heimlich will:
- Provide a detailed introduction to HCA with multicellular 3D models for drug discovery
- Review platform requirements and recommendations
- Present two case studies to illustrate the power of HCA in complex drug discovery applications
A Novel, High-Resolution Perifusion Platform for Studying Insulin Release Dynamics of Single Human Pancreatic Islets
Pancreatic islet perifusion assays have long been used to measure dynamic hormone release from islet cells in response to specific stimuli, however implementing a reliable, highly reproducible, yet simple method to assess human islet function remains challenging. In this new webinar, InSphero Head of Islet Solutions, Dr. Burcak Yesilag teams up with Dr. Patrick Misun of the ETH Zürich Department of Biosystems Science and Engineering, to discuss how dynamic insulin release can be studied in vitro using a novel microfluidic perifusion system. They will present results of their collaborative study, recently published in Advanced BioSystems, and offer their vision for the future of preclinical islet research. You will learn:
- Limitations of pancreatic islet perifusion assays that rely on pooling multiple islets per experimental condition
- Model requirements for reliably measuring secretion dynamics of a single human islet in vitro, using our 3D InSight™ Diabetes Platform for islet research as an example
- How the newly engineered microfluidic hanging-drop-based perifusion platform was used to study dynamic insulin release from single islets at high temporal resolution
Redefining NASH Drug Discovery: A New Approach to Complex Disease Modeling
Non-alcoholic steatohepatitis (NASH) is a progressive disease that takes years to develop in humans and involves an intricate interplay of multiple liver cell types, impaired liver functionality, and disrupted signaling. InSphero Senior Application Scientist Dr. Sue Grepper will present a versatile platform for screening and testing NASH therapies using pathophysiologically relevant, disease-tunable 3D in vitro human models. You will learn how our models can be applied to:
- Recapitulate hallmarks of NASH pathology, such as fatty liver, inflammation and fibrosis
- Assess compound and treatment effects on NASH with scalable, quantitative endpoints
- Confirm perturbation of key pathways involved in disease progression
A Novel Framework for Teasing Out Mechanisms of DILI
In this webinar from the SOT 2020 program, InSphero CSO and Toxicologist Prof. Armin Wolf and Liver Toxicology Team Leader Dr. Monika Kijanska will introduce a framework for mechanistic toxicology investigations, based on a suite of causality assays developed for our 3D InSight™ Liver Toxicology Platform. Armin and Monika will discuss how to design experimental programs that help validate relationships between events that trigger toxic responses and identify adverse outcome pathways implicated in drug-induced liver injury, and present example data generated using our liver toxicology platform. You will learn:
- How one simple, proven causality assay applied using different models at different time points can help tease out mechanisms of DILI
- How to tune and adapt 3D-optimized causality assays for a wide range of pathways using specific pathway modulators for DILI-specific mechanistic investigations and mechanism based screening
- Advantages of using a scalable, robust, and versatile 3D in vitro platform for liver toxicology studies
Optimizing 3D Spheroid Models for Efficient Drug-Induced Liver Injury Screening
In this webinar, the second in a series of toxicology sessions, InSphero Senior Application Scientist Dr. Sue Grepper will discuss why drug-induced liver injury (DILI) remains a major cause of drug attrition in the pharmaceutical industry. Sue will provide guidelines for integrating human 3D liver models into the drug development workflow to more efficiently screen for DILI compounds earlier in the preclinical phase, using our 3D InSight™ Liver Toxicology Platform as an example. You will learn:
- Why human 3D liver models outperform traditional 2D hepatocyte cultures
- Requirements for predictive DILI screening using human 3D liver models
- Industry trends and future outlook for predictive liver toxicology